Pakianathan Deepika's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Jun 10, 2022
- Accession no.
- 0000899243-22-021957
- Filed
- Jun 10, 2022
- Trade date
- Jun 8-10, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $3.43M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pakianathan DeepikaCIK 0001270734 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2022 | Common Stock | SSaleDisposed | −322,825 | $6.50F1 | −$2,098,362.5 | 1,918,298 | Indirect | |
| Jun 8, 2022 | Common Stock | SSaleDisposed | −3,152 | $6.50F1 | −$20,488 | 18,731 | Indirect | |
| Jun 9, 2022 | Common Stock | SSaleDisposed | −209,455 | $6.18F1 | −$1,294,431.9 | 1,708,843 | Indirect | |
| Jun 9, 2022 | Common Stock | SSaleDisposed | −2,045 | $6.18F1 | −$12,638.1 | 16,686 | Indirect | |
| Jun 10, 2022 | Common Stock | SSaleDisposed | −1,294 | $6.00F1 | −$7,764 | 1,707,549 | Indirect | |
| Jun 10, 2022 | Common Stock | SSaleDisposed | −13 | $6.00F1 | −$78 | 16,673 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 6 transactions in Table I.